Elsevier

Annals of Oncology

Volume 7, Issue 1, January 1996, Pages 65-70
Annals of Oncology

Original articles
Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation

https://doi.org/10.1093/oxfordjournals.annonc.a010481Get rights and content
Under an Elsevier user license
open archive

Summary

Background

The primary aim was to induce a high number of pCR in early (FIGO IC, IIB + C) – and advanced (FIGO ffl – IV) – stage ovarian cancer with a surgery plus 4 cycles of cisplatin and meiphalan (PAMP) regimen. The second objective was to prevent relapse with WAR in patients in remission after chemotherapy.

Patients and methods

218 eligible patients were treated after staging laparotomy with cisplatin 80 mg/sqm iv. on day 1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Response was verified by second-look laparotomy. WAR was carried out with the open field technique on a linear accele rator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with pathological or clinical CR or pathological PR with microscopical residual disease.

Results

146/218 patients (67%, 95% CI: 61%–73%) responded to PAMIP: 56 (26%) achieved pCR, 24 (11%), cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p = pathological). Multivariate analyses revealed that in advanced stages (92 cases in remission), the achievement of pCR was the most important factor for longer time to failure (TIF) and survival. Only 5 1/118 (43%) patients in remission received WAR Early-stage patients < = 55 years were more likely to have WAR than patients older than 55 years (77% vs. 23%; p = 0.02). Advanced-stage patients with cCR were less likely to be irradiated than patients with pCR or pPR (10% vs. 51%; p = 0.003). Toxicity of PAMP was acceptable with 10% of WHO grade 4 hematologic toxicity. Acute hematological toxicity of WAR caused interruption (33%) or incompleteness (33%) of irradiation in the majority of patients.

Conclusions

PAMP is an effective treatment for advanced ovarian cancer with a 67% response rate after 4 cycles. For the majority of patients in remission, WAR as a consolidation treatment was hardly feasible. For these patients new treatment modalities to consolidate remission are needed.

Key words

advanced ovarian cancer
chemotherapy
cisplatin
melphalan
second-look surgery
whole abdominal radiation

Cited by (0)